- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02068781
Aldosterone, Microvascular Function and Salt-sensitivity
Aldosterone-induced Microvascular Dysfunction as a Cause of Salt-sensitivity in Obesity?
Currently, the incidence of obesity and obesity-related disorders is reaching epidemic proportions, which entails an increasing burden for health care systems. The association of obesity with other risk factors for type 2 diabetes mellitus and cardiovascular disease, such as insulin resistance and hypertension, is often referred to as the metabolic syndrome. During recent years, salt-sensitivity of blood pressure has emerged as an additional cardiovascular risk factor that is related to obesity and other key components of the metabolic syndrome. The underlying pathophysiological mechanisms of these interrelationships are complex and incompletely elucidated. Microvascular dysfunction has been proposed as a link between insulin resistance and hypertension in obese individuals. In addition, impairment of microvascular function was found to be associated with salt-sensitivity of blood pressure. Increased aldosterone levels, as observed in obese individuals, might be a cause of microvascular dysfunction-induced salt-sensitivity and insulin resistance. Aldosterone not only gives rise to sodium-retention in the distal tubule of the kidney, but was also found to impair endothelial function and thus lower NO-availability, which is characteristic of microvascular dysfunction. In addition, elevated aldosterone levels are associated with both hypertension and insulin resistance, which is illustrated in patients with primary aldosteronism, but also in the general population.
The investigators hypothesize that increased aldosterone levels in obese individuals lead to impairment of microvascular function through reduction of NO-availability. This microvascular dysfunction is suggested to play a central role in the pathogenesis of salt-sensitive hypertension and insulin resistance.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Limburg
-
Maastricht, Limburg, Holland, 6229 ER
- Maastricht University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Obese individuals
- Age 18-65 years
- Caucasian
- Waist circumference > 102 cm (men)/> 88 cm (women)
Lean individuals
- Age 18-65 years
- Caucasian
- Waist circumference < 94 cm (men)/< 80 cm (women)
Exclusion Criteria:
Obese/lean individuals
- Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
- Diabetes mellitus/impaired glucose metabolism (fasting glucose values > 5.6 mmol/L
- Stage 3 hypertension (blood pressure > 180/110 mm Hg)
- Unstable or severe pulmonary disease
- Unstable or severe thyroid disorders
- Inflammatory diseases
- Smoking
- Alcohol use > 2 U/day (women)/> 3 U/day (men)
- Use of antihypertensive, lipid-lowering or glucose-lowering medications
- Use of corticosteroids and regular use of NSAIDs
- eGFR< 60 mL/min
- Impairment of hepatic function
- Pregnancy or lactation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Start with low-sodium diet
One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
|
50 mmol NaCl per 24h
250 mmol NaCl per 24h
|
|
Aktiv komparator: Start with high-sodium diet
One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
|
50 mmol NaCl per 24h
250 mmol NaCl per 24h
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Difference in capillary recruitment between low- and high sodium diets
Tidsramme: One week low-sodium diet; wash-out period of two weeks; one week high-sodium diet; order of respective diets is randomized
|
One week low-sodium diet; wash-out period of two weeks; one week high-sodium diet; order of respective diets is randomized
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: C.D.A. Stehouwer, MD, PhD, Maastricht University Medical Center
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 47438/IMP10124
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forhøjet blodtryk
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Inhibikase TherapeuticsIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Rutgers, The State University of New JerseyRekrutteringPulmonal arteriel hypertension | Pulmonal hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension af medfødt hjertesygdom | Pulmonal arteriel hypertension forbundet med skistosomiasis (lidelse) | Pulmonal arteriel og kronisk tromboembolisk pulmonal... og andre forholdForenede Stater
-
BackBeat Medical IncIkke rekrutterer endnuHypertension, systolisk | Hypertension (HTN) | Hjertesvigt med bevaret ejektionsfraktion (HFpEF)Georgien
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
Kliniske forsøg med Low-sodium diet
-
Wake Forest University Health SciencesTrukket tilbageDyspepsi | KostændringerForenede Stater
-
Boston Children's HospitalIkke rekrutterer endnuGastrostomi | Forhåbning | Ernæringsbesvær
-
Warsaw University of Life SciencesAfsluttetTyndtarmsbakterieovervækst | SIBO | Bakterieovervækstsyndrom i tyndtarmen (SIBO)Polen
-
Cairo UniversityRekrutteringFedme | Irritabelt tarmsyndrom | Abdominal fedmeEgypten
-
University Hospital, RouenAfsluttet
-
Boston Children's HospitalRekrutteringGastrostomi | Forhåbning | ErnæringsbesværForenede Stater
-
University of BariAfsluttetFunktionelle gastrointestinale lidelser | IBSItalien
-
Gødstrup HospitalIkke rekrutterer endnuHøjt blodtryk | Natrium overskud | Dialyseafhængig kronisk nyresygdom | DialysepatienterDanmark
-
University Hospital, BordeauxAfsluttet
-
Baylor College of MedicineUniversity of WashingtonAfsluttetForudsiger biomarkører reaktion på et pædiatrisk program til behandling af kroniske smertesymptomer?Irritabelt tarmsyndrom | Funktionelle mavesmerter | Funktionelle gastrointestinale lidelser | Funktionelt abdominalt smertesyndrom | Funktionel tarmsygdom | Funktionelle mavesmerterForenede Stater